IL134259A0 - Use of physiologically acceptable vanadium compounds, salts and complexes - Google Patents

Use of physiologically acceptable vanadium compounds, salts and complexes

Info

Publication number
IL134259A0
IL134259A0 IL13425998A IL13425998A IL134259A0 IL 134259 A0 IL134259 A0 IL 134259A0 IL 13425998 A IL13425998 A IL 13425998A IL 13425998 A IL13425998 A IL 13425998A IL 134259 A0 IL134259 A0 IL 134259A0
Authority
IL
Israel
Prior art keywords
physiologically acceptable
complexes
salts
vanadium compounds
acceptable vanadium
Prior art date
Application number
IL13425998A
Other languages
English (en)
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Publication of IL134259A0 publication Critical patent/IL134259A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL13425998A 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes IL134259A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes

Publications (1)

Publication Number Publication Date
IL134259A0 true IL134259A0 (en) 2001-04-30

Family

ID=19765422

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13425998A IL134259A0 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
IL134259A IL134259A (en) 1997-07-29 2000-01-27 Use of physiologically acceptable vanadium compounds, salts and complexes in the preparation of pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134259A IL134259A (en) 1997-07-29 2000-01-27 Use of physiologically acceptable vanadium compounds, salts and complexes in the preparation of pharmaceutical compositions

Country Status (22)

Country Link
US (2) US6579540B1 (xx)
EP (1) EP1001792B1 (xx)
JP (1) JP2001511454A (xx)
CN (1) CN1104244C (xx)
AT (1) ATE253373T1 (xx)
AU (1) AU738701B2 (xx)
BR (1) BR9811298A (xx)
CA (1) CA2298645C (xx)
CZ (1) CZ299716B6 (xx)
DE (1) DE69819514T2 (xx)
DK (1) DK1001792T3 (xx)
EA (1) EA002574B1 (xx)
ES (1) ES2207851T3 (xx)
ID (1) ID24870A (xx)
IL (2) IL134259A0 (xx)
NL (1) NL1006681C2 (xx)
NO (1) NO20000446L (xx)
NZ (1) NZ502613A (xx)
PL (1) PL338415A1 (xx)
PT (1) PT1001792E (xx)
TR (1) TR200000349T2 (xx)
WO (1) WO1999006056A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
WO2001045716A1 (en) * 1999-12-20 2001-06-28 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
ES2485384T3 (es) 2007-01-31 2014-08-13 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y/o mayor resistencia al estrés abiótico y un procedimiento para fabricar las mismas
ES2542311T3 (es) 2007-05-03 2015-08-04 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y un procedimiento de producción de las mismas
EP2987861A1 (en) 2007-07-20 2016-02-24 BASF Plant Science GmbH Plants having increased yield-related traits and a method for making the same
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
MX2010004305A (es) 2007-10-29 2010-04-30 Basf Plant Science Gmbh Plantas que tienen rasgos relacionados con el rendimiento aumentado y un metodo para producirlas.
EP2274431A1 (en) 2008-05-05 2011-01-19 BASF Plant Science GmbH Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
EP2523672B1 (en) 2010-01-15 2016-07-13 Rutgers, the State University of New Jersey Use of vanadium compounds to accelerate bone healing
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
CA2820297C (en) 2010-12-10 2019-06-25 University Of Medicine And Dentistry Of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
AU2012226703A1 (en) 2011-03-07 2013-10-17 Cfm Pharma Holding Bv Use of vanadium compounds for maintaining normaglycemia in a mammal
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
NO20000446L (no) 2000-03-24
ATE253373T1 (de) 2003-11-15
TR200000349T2 (tr) 2000-09-21
WO1999006056A1 (en) 1999-02-11
PT1001792E (pt) 2004-03-31
PL338415A1 (en) 2000-11-06
US6579540B1 (en) 2003-06-17
CZ2000326A3 (cs) 2000-07-12
EP1001792B1 (en) 2003-11-05
IL134259A (en) 2010-02-17
NL1006681C2 (nl) 1999-02-08
NZ502613A (en) 2001-08-31
EA200000176A1 (ru) 2000-10-30
CA2298645C (en) 2004-05-18
ID24870A (id) 2000-08-31
EP1001792A1 (en) 2000-05-24
AU8650598A (en) 1999-02-22
JP2001511454A (ja) 2001-08-14
US20030211170A1 (en) 2003-11-13
CA2298645A1 (en) 1999-02-11
AU738701B2 (en) 2001-09-27
DE69819514D1 (de) 2003-12-11
CN1270525A (zh) 2000-10-18
DE69819514T2 (de) 2004-09-23
ES2207851T3 (es) 2004-06-01
EA002574B1 (ru) 2002-06-27
NO20000446D0 (no) 2000-01-28
BR9811298A (pt) 2000-08-29
CZ299716B6 (cs) 2008-10-29
DK1001792T3 (da) 2004-01-19
CN1104244C (zh) 2003-04-02

Similar Documents

Publication Publication Date Title
IL134259A0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
CA2385755A1 (en) Prevention of colorectal cancer
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
CA2394471A1 (en) External preparation for treating pruritus
BG106151A (en) Pharmaceutical complex
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
WO2001045717A3 (en) Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
GR20010100390A (el) Χρηση του diclofenac h αποδεκτων αλατων αυτου για την αντιμετωπιση των εγκαυματων.
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
WO1998042312A3 (en) Medicament having sclerosing activity
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
CZ176395A3 (en) The use of riluzol for preparing medicaments acceptable as antidotes against harmful effects of irradiation
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом